This matters for Australia because it provides the first real-world signal that medicines may be able to bend the obesity curve at scale. This is something that decades of lifestyle-only interventions have failed to achieve. Yet, despite this promise, access in Australia remains confined to those who can pay privately.
Obesity medicines, the limits of the PBS, and the test of policy imagination
January 28, 2026 Latest NewsBioPharmaComment
Latest Video
New Stories
-
New digital health reforms to give Australians a more complete medicines history
January 28, 2026 - - Latest News -
Peer-reviewed validation strengthens Paradigm’s osteoarthritis program
January 28, 2026 - - Australian Biotech -
Obesity medicines, the limits of the PBS, and the test of policy imagination
January 28, 2026 - - Latest News -
Patrys completes Reliis acquisition, expands clinical pipeline and strengthens board
January 28, 2026 - - Australian Biotech -
Trump administration launches third round of price negotiations, including the first renegotiation
January 28, 2026 - - Latest News -
UK life sciences report highlights pressures familiar to Australian industry
January 27, 2026 - - Latest News -
Americans pay a much lower share of health costs than we do in Australia
January 27, 2026 - - Latest News

